favipiravir - versus control - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.12 [0.02, 62.74]< 10%1 study (1/-)47.9 %some concernnot evaluable moderatecrucial-
clinical improvement 1.25 [0.21, 7.62]> 10%1 study (1/-)59.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.25 [0.21, 7.62]> 10%1 study (1/-)59.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.18 [0.01, 4.75]> 10%1 study (1/-)15.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 0.18 [0.01, 4.75]> 10%1 study (1/-)15.7 %some concernnot evaluable moderateimportant-
ICU admission 5.43 [0.21, 139.89]< 10%1 study (1/-)15.7 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.